Molecular imaging of tumor angiogenesis

Nick G. Costouros, Felix E. Diehn, Steven K. Libutti

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

The emergence of angiogenesis as an important target for cancer therapy has led to increased research aimed at understanding the mechanisms underlying the development, maintenance, and destruction of tumor vasculature. Concurrently, molecular imaging technologies have been developed and are being incorporated as integral components of biomedical research due to their ability to noninvasively monitor in vivo molecular events. With the evaluation of numerous anti-angiogenic agents in clinical trials, the adaptation and validation of molecular imaging modalities for monitoring angiogenesis is actively being pursued. The importance of selecting appropriate molecular targets in the study of angiogenesis has become increasingly complex due to the pleiotropy of vascular phenotypes. Furthermore, due to both the relatively low abundance of endothelial cells in tumor tissue and the inherent difficulties of detecting molecular events, molecular imaging of vasculature necessitates continued improvements in achieving higher sensitivity. While several studies have been published that set the groundwork for imaging angiogenesis, much has yet to be accomplished. Various tumor models and transgenic mice provide an excellent resource for developing molecular imaging technologies for the understanding of angiogenesis. This research may play a particularly crucial role in evaluating mechanism and efficacy during pre-clinical testing of anti-angiogenic drugs. Due to practical limitations, however, the implementation of angiogenesis-directed molecular imaging may not extend beyond highly specialized clinical trials. That is, imaging modalities that evaluate angiogenesis at a functional level may prove more appropriate. Despite future technical challenges, molecular imaging will become an important research and clinical tool in evaluating tumor angiogenesis.

Original languageEnglish (US)
Pages (from-to)72-78
Number of pages7
JournalJournal of Cellular Biochemistry
Issue numberSUPPL. 39
StatePublished - 2002
Externally publishedYes

Fingerprint

Molecular imaging
Molecular Imaging
Tumors
Neoplasms
Research
Clinical Trials
Technology
Imaging techniques
Angiogenesis Inhibitors
Endothelial cells
Transgenic Mice
Blood Vessels
Biomedical Research
Endothelial Cells
Maintenance
Tissue
Phenotype
Monitoring
Testing

Keywords

  • Intravital videomicroscopy
  • Magnetic resonance imaging
  • Optical imaging
  • Positron emission tomography
  • Ultrasound

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology

Cite this

Costouros, N. G., Diehn, F. E., & Libutti, S. K. (2002). Molecular imaging of tumor angiogenesis. Journal of Cellular Biochemistry, (SUPPL. 39), 72-78.

Molecular imaging of tumor angiogenesis. / Costouros, Nick G.; Diehn, Felix E.; Libutti, Steven K.

In: Journal of Cellular Biochemistry, No. SUPPL. 39, 2002, p. 72-78.

Research output: Contribution to journalArticle

Costouros, NG, Diehn, FE & Libutti, SK 2002, 'Molecular imaging of tumor angiogenesis', Journal of Cellular Biochemistry, no. SUPPL. 39, pp. 72-78.
Costouros NG, Diehn FE, Libutti SK. Molecular imaging of tumor angiogenesis. Journal of Cellular Biochemistry. 2002;(SUPPL. 39):72-78.
Costouros, Nick G. ; Diehn, Felix E. ; Libutti, Steven K. / Molecular imaging of tumor angiogenesis. In: Journal of Cellular Biochemistry. 2002 ; No. SUPPL. 39. pp. 72-78.
@article{24295ecc349f4406bf87392d4b367693,
title = "Molecular imaging of tumor angiogenesis",
abstract = "The emergence of angiogenesis as an important target for cancer therapy has led to increased research aimed at understanding the mechanisms underlying the development, maintenance, and destruction of tumor vasculature. Concurrently, molecular imaging technologies have been developed and are being incorporated as integral components of biomedical research due to their ability to noninvasively monitor in vivo molecular events. With the evaluation of numerous anti-angiogenic agents in clinical trials, the adaptation and validation of molecular imaging modalities for monitoring angiogenesis is actively being pursued. The importance of selecting appropriate molecular targets in the study of angiogenesis has become increasingly complex due to the pleiotropy of vascular phenotypes. Furthermore, due to both the relatively low abundance of endothelial cells in tumor tissue and the inherent difficulties of detecting molecular events, molecular imaging of vasculature necessitates continued improvements in achieving higher sensitivity. While several studies have been published that set the groundwork for imaging angiogenesis, much has yet to be accomplished. Various tumor models and transgenic mice provide an excellent resource for developing molecular imaging technologies for the understanding of angiogenesis. This research may play a particularly crucial role in evaluating mechanism and efficacy during pre-clinical testing of anti-angiogenic drugs. Due to practical limitations, however, the implementation of angiogenesis-directed molecular imaging may not extend beyond highly specialized clinical trials. That is, imaging modalities that evaluate angiogenesis at a functional level may prove more appropriate. Despite future technical challenges, molecular imaging will become an important research and clinical tool in evaluating tumor angiogenesis.",
keywords = "Intravital videomicroscopy, Magnetic resonance imaging, Optical imaging, Positron emission tomography, Ultrasound",
author = "Costouros, {Nick G.} and Diehn, {Felix E.} and Libutti, {Steven K.}",
year = "2002",
language = "English (US)",
pages = "72--78",
journal = "Journal of Cellular Biochemistry",
issn = "0730-2312",
publisher = "Wiley-Liss Inc.",
number = "SUPPL. 39",

}

TY - JOUR

T1 - Molecular imaging of tumor angiogenesis

AU - Costouros, Nick G.

AU - Diehn, Felix E.

AU - Libutti, Steven K.

PY - 2002

Y1 - 2002

N2 - The emergence of angiogenesis as an important target for cancer therapy has led to increased research aimed at understanding the mechanisms underlying the development, maintenance, and destruction of tumor vasculature. Concurrently, molecular imaging technologies have been developed and are being incorporated as integral components of biomedical research due to their ability to noninvasively monitor in vivo molecular events. With the evaluation of numerous anti-angiogenic agents in clinical trials, the adaptation and validation of molecular imaging modalities for monitoring angiogenesis is actively being pursued. The importance of selecting appropriate molecular targets in the study of angiogenesis has become increasingly complex due to the pleiotropy of vascular phenotypes. Furthermore, due to both the relatively low abundance of endothelial cells in tumor tissue and the inherent difficulties of detecting molecular events, molecular imaging of vasculature necessitates continued improvements in achieving higher sensitivity. While several studies have been published that set the groundwork for imaging angiogenesis, much has yet to be accomplished. Various tumor models and transgenic mice provide an excellent resource for developing molecular imaging technologies for the understanding of angiogenesis. This research may play a particularly crucial role in evaluating mechanism and efficacy during pre-clinical testing of anti-angiogenic drugs. Due to practical limitations, however, the implementation of angiogenesis-directed molecular imaging may not extend beyond highly specialized clinical trials. That is, imaging modalities that evaluate angiogenesis at a functional level may prove more appropriate. Despite future technical challenges, molecular imaging will become an important research and clinical tool in evaluating tumor angiogenesis.

AB - The emergence of angiogenesis as an important target for cancer therapy has led to increased research aimed at understanding the mechanisms underlying the development, maintenance, and destruction of tumor vasculature. Concurrently, molecular imaging technologies have been developed and are being incorporated as integral components of biomedical research due to their ability to noninvasively monitor in vivo molecular events. With the evaluation of numerous anti-angiogenic agents in clinical trials, the adaptation and validation of molecular imaging modalities for monitoring angiogenesis is actively being pursued. The importance of selecting appropriate molecular targets in the study of angiogenesis has become increasingly complex due to the pleiotropy of vascular phenotypes. Furthermore, due to both the relatively low abundance of endothelial cells in tumor tissue and the inherent difficulties of detecting molecular events, molecular imaging of vasculature necessitates continued improvements in achieving higher sensitivity. While several studies have been published that set the groundwork for imaging angiogenesis, much has yet to be accomplished. Various tumor models and transgenic mice provide an excellent resource for developing molecular imaging technologies for the understanding of angiogenesis. This research may play a particularly crucial role in evaluating mechanism and efficacy during pre-clinical testing of anti-angiogenic drugs. Due to practical limitations, however, the implementation of angiogenesis-directed molecular imaging may not extend beyond highly specialized clinical trials. That is, imaging modalities that evaluate angiogenesis at a functional level may prove more appropriate. Despite future technical challenges, molecular imaging will become an important research and clinical tool in evaluating tumor angiogenesis.

KW - Intravital videomicroscopy

KW - Magnetic resonance imaging

KW - Optical imaging

KW - Positron emission tomography

KW - Ultrasound

UR - http://www.scopus.com/inward/record.url?scp=0036983869&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036983869&partnerID=8YFLogxK

M3 - Article

C2 - 12552605

AN - SCOPUS:0036983869

SP - 72

EP - 78

JO - Journal of Cellular Biochemistry

JF - Journal of Cellular Biochemistry

SN - 0730-2312

IS - SUPPL. 39

ER -